Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide vs Mesalazine in Moderately Active Crohn's Disease
NCT00300118Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Sep 2004
- Primary completion
- May 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide in Crohn's disease (2 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Rate of remission at 8 weeks. Started Sep 2004; status: completed.
02
Drugs
budesonide
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00300118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00300118.